Equities

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd

Actions
  • Price (HKD)175.00
  • Today's Change-7.20 / -3.95%
  • Shares traded312.40k
  • 1 Year change+94.77%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments2,4889382
Total Receivables, Net12410471
Total Inventory635351
Prepaid expenses925631
Other current assets, total402665
Total current assets2,807332298
Property, plant & equipment, net701658514
Goodwill, net------
Intangibles, net1.343.180.49
Long term investments------
Note receivable - long term------
Other long term assets------
Total assets3,510993813
LIABILITIES
Accounts payable404358354
Accrued expenses1378947
Notes payable/short-term debt02,8912,388
Current portion long-term debt/capital leases54821.66
Other current liabilities, total514747654
Total current liabilities1,1104,1673,445
Total long term debt5.51411.25
Total debt603,0142,391
Deferred income tax------
Minority interest------
Other liabilities, total651111
Total liabilities1,1804,2193,457
SHAREHOLDERS EQUITY
Common stock219107107
Additional paid-in capital------
Retained earnings (accumulated deficit)2,105(3334)(2738)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total5.540.75(13)
Total equity2,329(3226)(2644)
Total liabilities & shareholders' equity3,510993813
Total common shares outstanding219216216
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.